{"transactions":[{"id":941229,"issuer":{"id":4711,"kind":"organization","name":"Aktis Oncology, Inc.","symbol":"AKTS"},"owners":[{"id":69540,"kind":"organization","name":"Vida Ventures II, LLC","position":1,"cik":"0001776851","reported_name":"Vida Ventures II, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":69541,"kind":"organization","name":"VIDA VENTURES II-A, LLC","position":2,"cik":"0001781930","reported_name":"VIDA VENTURES II-A, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Redeemable Convertible Preferred Stock","published_at":"2026-01-12T22:10:07.000Z","date":"2026-01-12","kind":"exercise","planned":false,"acquired":false,"shares":101250,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F5","text":"The Series B Redeemable Convertible Preferred Stock had no expiration date and automatically converted into the Issuer's Common Stock on a 3.8044-for-1 basis immediately prior to the closing of the Issuer's initial public offering of its Common Stock without payment of additional consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The Series B Redeemable Convertible Preferred Stock had no expiration date and automatically converted into the Issuer's Common Stock on a 3.8044-for-1 basis immediately prior to the closing of the Issuer's initial public offering of its Common Stock without payment of additional consideration."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"The Series B Redeemable Convertible Preferred Stock had no expiration date and automatically converted into the Issuer's Common Stock on a 3.8044-for-1 basis immediately prior to the closing of the Issuer's initial public offering of its Common Stock without payment of additional consideration."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These shares are held by Vida Ventures II-A, LLC (\"VV II-A\"). VVM II is the manager of VV II-A and may be deemed to have voting, investment and dispositive power with respect to the shares held by VV II-A. Arie Belldegrun, Fred Cohen, and Leonard Potter, the members of the management committee of VVM II, along with the other members of the investment committee of VVM II, Rajul Jain, Joshua Kazam, and Helen Kim, a member of the Issuer's board of directors, may be deemed to share voting, investment and dispositive power over the shares held by VV II-A and each such person disclaims beneficial ownership of the securities except to the extent of such person's pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":26613},"source":{"system":"sec-edgar","filing":"0001193125-26-010617","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/2035832/000119312526010617/ownership.xml","form_type":"4"}},{"id":941228,"issuer":{"id":4711,"kind":"organization","name":"Aktis Oncology, Inc.","symbol":"AKTS"},"owners":[{"id":69540,"kind":"organization","name":"Vida Ventures II, LLC","position":1,"cik":"0001776851","reported_name":"Vida Ventures II, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":69541,"kind":"organization","name":"VIDA VENTURES II-A, LLC","position":2,"cik":"0001781930","reported_name":"VIDA VENTURES II-A, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Redeemable Convertible Preferred Stock","published_at":"2026-01-12T22:10:07.000Z","date":"2026-01-12","kind":"exercise","planned":false,"acquired":false,"shares":3648750,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F5","text":"The Series B Redeemable Convertible Preferred Stock had no expiration date and automatically converted into the Issuer's Common Stock on a 3.8044-for-1 basis immediately prior to the closing of the Issuer's initial public offering of its Common Stock without payment of additional consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The Series B Redeemable Convertible Preferred Stock had no expiration date and automatically converted into the Issuer's Common Stock on a 3.8044-for-1 basis immediately prior to the closing of the Issuer's initial public offering of its Common Stock without payment of additional consideration."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"The Series B Redeemable Convertible Preferred Stock had no expiration date and automatically converted into the Issuer's Common Stock on a 3.8044-for-1 basis immediately prior to the closing of the Issuer's initial public offering of its Common Stock without payment of additional consideration."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are held by Vida Ventures II, LLC (\"VV II\"). VV Manager II, LLC (\"VVM II\") is the manager of VV II and may be deemed to have voting, investment and dispositive power with respect to the shares held by VV II. Arie Belldegrun, Fred Cohen, and Leonard Potter, the members of the management committee of VVM II, along with the other members of the investment committee of VVM II, Rajul Jain, Joshua Kazam, and Helen Kim, a member of the Issuer's board of directors, may be deemed to share voting, investment and dispositive power over the shares held by VV II and each such person disclaims beneficial ownership of the securities except to the extent of such person's pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":959086},"source":{"system":"sec-edgar","filing":"0001193125-26-010617","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/2035832/000119312526010617/ownership.xml","form_type":"4"}},{"id":941227,"issuer":{"id":4711,"kind":"organization","name":"Aktis Oncology, Inc.","symbol":"AKTS"},"owners":[{"id":69540,"kind":"organization","name":"Vida Ventures II, LLC","position":1,"cik":"0001776851","reported_name":"Vida Ventures II, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":69541,"kind":"organization","name":"VIDA VENTURES II-A, LLC","position":2,"cik":"0001781930","reported_name":"VIDA VENTURES II-A, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Redeemable Convertible Preferred Stock","published_at":"2026-01-12T22:10:07.000Z","date":"2026-01-12","kind":"exercise","planned":false,"acquired":false,"shares":411750,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"The Series A Redeemable Convertible Preferred Stock had no expiration date and automatically converted into the Issuer's Common Stock on a 3.8044-for-1 basis immediately prior to the closing of the Issuer's initial public offering of its Common Stock without payment of additional consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The Series A Redeemable Convertible Preferred Stock had no expiration date and automatically converted into the Issuer's Common Stock on a 3.8044-for-1 basis immediately prior to the closing of the Issuer's initial public offering of its Common Stock without payment of additional consideration."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The Series A Redeemable Convertible Preferred Stock had no expiration date and automatically converted into the Issuer's Common Stock on a 3.8044-for-1 basis immediately prior to the closing of the Issuer's initial public offering of its Common Stock without payment of additional consideration."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These shares are held by Vida Ventures II-A, LLC (\"VV II-A\"). VVM II is the manager of VV II-A and may be deemed to have voting, investment and dispositive power with respect to the shares held by VV II-A. Arie Belldegrun, Fred Cohen, and Leonard Potter, the members of the management committee of VVM II, along with the other members of the investment committee of VVM II, Rajul Jain, Joshua Kazam, and Helen Kim, a member of the Issuer's board of directors, may be deemed to share voting, investment and dispositive power over the shares held by VV II-A and each such person disclaims beneficial ownership of the securities except to the extent of such person's pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":108229},"source":{"system":"sec-edgar","filing":"0001193125-26-010617","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/2035832/000119312526010617/ownership.xml","form_type":"4"}},{"id":941226,"issuer":{"id":4711,"kind":"organization","name":"Aktis Oncology, Inc.","symbol":"AKTS"},"owners":[{"id":69540,"kind":"organization","name":"Vida Ventures II, LLC","position":1,"cik":"0001776851","reported_name":"Vida Ventures II, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":69541,"kind":"organization","name":"VIDA VENTURES II-A, LLC","position":2,"cik":"0001781930","reported_name":"VIDA VENTURES II-A, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Redeemable Convertible Preferred Stock","published_at":"2026-01-12T22:10:07.000Z","date":"2026-01-12","kind":"exercise","planned":false,"acquired":false,"shares":14838250,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"The Series A Redeemable Convertible Preferred Stock had no expiration date and automatically converted into the Issuer's Common Stock on a 3.8044-for-1 basis immediately prior to the closing of the Issuer's initial public offering of its Common Stock without payment of additional consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The Series A Redeemable Convertible Preferred Stock had no expiration date and automatically converted into the Issuer's Common Stock on a 3.8044-for-1 basis immediately prior to the closing of the Issuer's initial public offering of its Common Stock without payment of additional consideration."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The Series A Redeemable Convertible Preferred Stock had no expiration date and automatically converted into the Issuer's Common Stock on a 3.8044-for-1 basis immediately prior to the closing of the Issuer's initial public offering of its Common Stock without payment of additional consideration."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are held by Vida Ventures II, LLC (\"VV II\"). VV Manager II, LLC (\"VVM II\") is the manager of VV II and may be deemed to have voting, investment and dispositive power with respect to the shares held by VV II. Arie Belldegrun, Fred Cohen, and Leonard Potter, the members of the management committee of VVM II, along with the other members of the investment committee of VVM II, Rajul Jain, Joshua Kazam, and Helen Kim, a member of the Issuer's board of directors, may be deemed to share voting, investment and dispositive power over the shares held by VV II and each such person disclaims beneficial ownership of the securities except to the extent of such person's pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":3900284},"source":{"system":"sec-edgar","filing":"0001193125-26-010617","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/2035832/000119312526010617/ownership.xml","form_type":"4"}},{"id":941225,"issuer":{"id":4711,"kind":"organization","name":"Aktis Oncology, Inc.","symbol":"AKTS"},"owners":[{"id":69540,"kind":"organization","name":"Vida Ventures II, LLC","position":1,"cik":"0001776851","reported_name":"Vida Ventures II, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":69541,"kind":"organization","name":"VIDA VENTURES II-A, LLC","position":2,"cik":"0001781930","reported_name":"VIDA VENTURES II-A, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-01-12T22:10:07.000Z","date":"2026-01-12","kind":"purchase","planned":false,"acquired":true,"shares":22545,"price":18,"value":405810.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These shares are held by Vida Ventures II-A, LLC (\"VV II-A\"). VVM II is the manager of VV II-A and may be deemed to have voting, investment and dispositive power with respect to the shares held by VV II-A. Arie Belldegrun, Fred Cohen, and Leonard Potter, the members of the management committee of VVM II, along with the other members of the investment committee of VVM II, Rajul Jain, Joshua Kazam, and Helen Kim, a member of the Issuer's board of directors, may be deemed to share voting, investment and dispositive power over the shares held by VV II-A and each such person disclaims beneficial ownership of the securities except to the extent of such person's pecuniary interest therein."}],"balance_after":157387,"source":{"system":"sec-edgar","filing":"0001193125-26-010617","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/2035832/000119312526010617/ownership.xml","form_type":"4"}},{"id":941224,"issuer":{"id":4711,"kind":"organization","name":"Aktis Oncology, Inc.","symbol":"AKTS"},"owners":[{"id":69540,"kind":"organization","name":"Vida Ventures II, LLC","position":1,"cik":"0001776851","reported_name":"Vida Ventures II, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":69541,"kind":"organization","name":"VIDA VENTURES II-A, LLC","position":2,"cik":"0001781930","reported_name":"VIDA VENTURES II-A, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-01-12T22:10:07.000Z","date":"2026-01-12","kind":"exercise","planned":false,"acquired":true,"shares":134842,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares of the Issuer's Common Stock received upon conversion of shares of the Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock on a 3.8044-for-1 basis without payment of additional consideration."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents shares of the Issuer's Common Stock received upon conversion of shares of the Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock on a 3.8044-for-1 basis without payment of additional consideration."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These shares are held by Vida Ventures II-A, LLC (\"VV II-A\"). VVM II is the manager of VV II-A and may be deemed to have voting, investment and dispositive power with respect to the shares held by VV II-A. Arie Belldegrun, Fred Cohen, and Leonard Potter, the members of the management committee of VVM II, along with the other members of the investment committee of VVM II, Rajul Jain, Joshua Kazam, and Helen Kim, a member of the Issuer's board of directors, may be deemed to share voting, investment and dispositive power over the shares held by VV II-A and each such person disclaims beneficial ownership of the securities except to the extent of such person's pecuniary interest therein."}],"balance_after":134842,"source":{"system":"sec-edgar","filing":"0001193125-26-010617","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/2035832/000119312526010617/ownership.xml","form_type":"4"}},{"id":941223,"issuer":{"id":4711,"kind":"organization","name":"Aktis Oncology, Inc.","symbol":"AKTS"},"owners":[{"id":69540,"kind":"organization","name":"Vida Ventures II, LLC","position":1,"cik":"0001776851","reported_name":"Vida Ventures II, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":69541,"kind":"organization","name":"VIDA VENTURES II-A, LLC","position":2,"cik":"0001781930","reported_name":"VIDA VENTURES II-A, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-01-12T22:10:07.000Z","date":"2026-01-12","kind":"purchase","planned":false,"acquired":true,"shares":812455,"price":18,"value":14624190.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are held by Vida Ventures II, LLC (\"VV II\"). VV Manager II, LLC (\"VVM II\") is the manager of VV II and may be deemed to have voting, investment and dispositive power with respect to the shares held by VV II. Arie Belldegrun, Fred Cohen, and Leonard Potter, the members of the management committee of VVM II, along with the other members of the investment committee of VVM II, Rajul Jain, Joshua Kazam, and Helen Kim, a member of the Issuer's board of directors, may be deemed to share voting, investment and dispositive power over the shares held by VV II and each such person disclaims beneficial ownership of the securities except to the extent of such person's pecuniary interest therein."}],"balance_after":5671825,"source":{"system":"sec-edgar","filing":"0001193125-26-010617","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2035832/000119312526010617/ownership.xml","form_type":"4"}},{"id":941222,"issuer":{"id":4711,"kind":"organization","name":"Aktis Oncology, Inc.","symbol":"AKTS"},"owners":[{"id":69540,"kind":"organization","name":"Vida Ventures II, LLC","position":1,"cik":"0001776851","reported_name":"Vida Ventures II, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":69541,"kind":"organization","name":"VIDA VENTURES II-A, LLC","position":2,"cik":"0001781930","reported_name":"VIDA VENTURES II-A, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-01-12T22:10:07.000Z","date":"2026-01-12","kind":"exercise","planned":false,"acquired":true,"shares":4859370,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares of the Issuer's Common Stock received upon conversion of shares of the Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock on a 3.8044-for-1 basis without payment of additional consideration."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents shares of the Issuer's Common Stock received upon conversion of shares of the Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock on a 3.8044-for-1 basis without payment of additional consideration."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are held by Vida Ventures II, LLC (\"VV II\"). VV Manager II, LLC (\"VVM II\") is the manager of VV II and may be deemed to have voting, investment and dispositive power with respect to the shares held by VV II. Arie Belldegrun, Fred Cohen, and Leonard Potter, the members of the management committee of VVM II, along with the other members of the investment committee of VVM II, Rajul Jain, Joshua Kazam, and Helen Kim, a member of the Issuer's board of directors, may be deemed to share voting, investment and dispositive power over the shares held by VV II and each such person disclaims beneficial ownership of the securities except to the extent of such person's pecuniary interest therein."}],"balance_after":4859370,"source":{"system":"sec-edgar","filing":"0001193125-26-010617","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2035832/000119312526010617/ownership.xml","form_type":"4"}},{"id":3023960,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":146475,"kind":"organization","name":"VV Manager II, LLC","position":1,"cik":"0001824569","reported_name":"VV Manager II, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":69540,"kind":"organization","name":"Vida Ventures II, LLC","position":2,"cik":"0001776851","reported_name":"Vida Ventures II, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":69541,"kind":"organization","name":"VIDA VENTURES II-A, LLC","position":3,"cik":"0001781930","reported_name":"VIDA VENTURES II-A, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Preferred Stock","published_at":"2020-09-23T19:11:31.000Z","date":"2020-09-21","kind":"exercise","acquired":false,"shares":192102,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"On September 21, 2020, the Series B Preferred Stock automatically converted into Common Stock on a 3.3169-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On September 21, 2020, the Series B Preferred Stock automatically converted into Common Stock on a 3.3169-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"On September 21, 2020, the Series B Preferred Stock automatically converted into Common Stock on a 3.3169-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The shares are held directly by Vida Ventures II-A, LLC (\"Vida II-A\"). VV Manager II is the manager of Vida II-A.  Each of the Management Committee ,the Investment Committee and the respective members thereof may be deemed to share voting and dispositive power over the shares held by Vida II-A. VV Manager II, the Management Committee, the Investment Committee and each member of  each of the Management Committee and Investment Committee disclaims beneficial ownership over the securities held of record by Vida II-A and this report shall not be deemed an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":57916},"source":{"system":"sec-edgar","filing":"0000899243-20-026193","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1824569/000089924320026193/doc4.xml","form_type":"4"}},{"id":3023959,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":146475,"kind":"organization","name":"VV Manager II, LLC","position":1,"cik":"0001824569","reported_name":"VV Manager II, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":69540,"kind":"organization","name":"Vida Ventures II, LLC","position":2,"cik":"0001776851","reported_name":"Vida Ventures II, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":69541,"kind":"organization","name":"VIDA VENTURES II-A, LLC","position":3,"cik":"0001781930","reported_name":"VIDA VENTURES II-A, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Preferred Stock","published_at":"2020-09-23T19:11:31.000Z","date":"2020-09-21","kind":"exercise","acquired":false,"shares":6922803,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"On September 21, 2020, the Series B Preferred Stock automatically converted into Common Stock on a 3.3169-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On September 21, 2020, the Series B Preferred Stock automatically converted into Common Stock on a 3.3169-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"On September 21, 2020, the Series B Preferred Stock automatically converted into Common Stock on a 3.3169-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are held directly by Vida Ventures II, LLC (\"Vida II\"). VV Manager II, LLC (\"VV Manager II\") is the manager of Vida II. Arie Belldegrun, Fred Cohen, and Leonard Potter are the members of the management committee of VV Manager II (the \"Management Committee\") and Stefan Vitorovic, Arjun Goyal, Helen Kim, Rajul Jain, and Joshua Kazam are the members of the investment committee of VV Manager II (the \"Investment Committee\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"(Continued from Footnote 2) Each of the Management Committee, the Investment Committee  and the respective members thereof may be deemed to share voting and dispositive power over the shares held by Vida II. VV Manager II, the Management Committee, the Investment Committee and each member of each of the Management Committee and Investment Committee disclaims beneficial ownership over the securities held of record by Vida II and this report shall not be deemed an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":2087130},"source":{"system":"sec-edgar","filing":"0000899243-20-026193","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1824569/000089924320026193/doc4.xml","form_type":"4"}},{"id":3023958,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":146475,"kind":"organization","name":"VV Manager II, LLC","position":1,"cik":"0001824569","reported_name":"VV Manager II, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":69540,"kind":"organization","name":"Vida Ventures II, LLC","position":2,"cik":"0001776851","reported_name":"Vida Ventures II, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":69541,"kind":"organization","name":"VIDA VENTURES II-A, LLC","position":3,"cik":"0001781930","reported_name":"VIDA VENTURES II-A, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-09-23T19:11:31.000Z","date":"2020-09-21","kind":"purchase","acquired":true,"shares":22005,"price":19,"value":418095.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The shares are held directly by Vida Ventures II-A, LLC (\"Vida II-A\"). VV Manager II is the manager of Vida II-A.  Each of the Management Committee ,the Investment Committee and the respective members thereof may be deemed to share voting and dispositive power over the shares held by Vida II-A. VV Manager II, the Management Committee, the Investment Committee and each member of  each of the Management Committee and Investment Committee disclaims beneficial ownership over the securities held of record by Vida II-A and this report shall not be deemed an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interest therein."}],"balance_after":79921,"source":{"system":"sec-edgar","filing":"0000899243-20-026193","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1824569/000089924320026193/doc4.xml","form_type":"4"}},{"id":3023957,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":146475,"kind":"organization","name":"VV Manager II, LLC","position":1,"cik":"0001824569","reported_name":"VV Manager II, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":69540,"kind":"organization","name":"Vida Ventures II, LLC","position":2,"cik":"0001776851","reported_name":"Vida Ventures II, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":69541,"kind":"organization","name":"VIDA VENTURES II-A, LLC","position":3,"cik":"0001781930","reported_name":"VIDA VENTURES II-A, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-09-23T19:11:31.000Z","date":"2020-09-21","kind":"exercise","acquired":true,"shares":57916,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On September 21, 2020, the Series B Preferred Stock automatically converted into Common Stock on a 3.3169-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The shares are held directly by Vida Ventures II-A, LLC (\"Vida II-A\"). VV Manager II is the manager of Vida II-A.  Each of the Management Committee ,the Investment Committee and the respective members thereof may be deemed to share voting and dispositive power over the shares held by Vida II-A. VV Manager II, the Management Committee, the Investment Committee and each member of  each of the Management Committee and Investment Committee disclaims beneficial ownership over the securities held of record by Vida II-A and this report shall not be deemed an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interest therein."}],"balance_after":57916,"source":{"system":"sec-edgar","filing":"0000899243-20-026193","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1824569/000089924320026193/doc4.xml","form_type":"4"}},{"id":3023956,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":146475,"kind":"organization","name":"VV Manager II, LLC","position":1,"cik":"0001824569","reported_name":"VV Manager II, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":69540,"kind":"organization","name":"Vida Ventures II, LLC","position":2,"cik":"0001776851","reported_name":"Vida Ventures II, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":69541,"kind":"organization","name":"VIDA VENTURES II-A, LLC","position":3,"cik":"0001781930","reported_name":"VIDA VENTURES II-A, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-09-23T19:11:31.000Z","date":"2020-09-21","kind":"purchase","acquired":true,"shares":792995,"price":19,"value":15066905.0,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are held directly by Vida Ventures II, LLC (\"Vida II\"). VV Manager II, LLC (\"VV Manager II\") is the manager of Vida II. Arie Belldegrun, Fred Cohen, and Leonard Potter are the members of the management committee of VV Manager II (the \"Management Committee\") and Stefan Vitorovic, Arjun Goyal, Helen Kim, Rajul Jain, and Joshua Kazam are the members of the investment committee of VV Manager II (the \"Investment Committee\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"(Continued from Footnote 2) Each of the Management Committee, the Investment Committee  and the respective members thereof may be deemed to share voting and dispositive power over the shares held by Vida II. VV Manager II, the Management Committee, the Investment Committee and each member of each of the Management Committee and Investment Committee disclaims beneficial ownership over the securities held of record by Vida II and this report shall not be deemed an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interest therein."}],"balance_after":2880125,"source":{"system":"sec-edgar","filing":"0000899243-20-026193","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1824569/000089924320026193/doc4.xml","form_type":"4"}},{"id":3023955,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":146475,"kind":"organization","name":"VV Manager II, LLC","position":1,"cik":"0001824569","reported_name":"VV Manager II, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":69540,"kind":"organization","name":"Vida Ventures II, LLC","position":2,"cik":"0001776851","reported_name":"Vida Ventures II, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":69541,"kind":"organization","name":"VIDA VENTURES II-A, LLC","position":3,"cik":"0001781930","reported_name":"VIDA VENTURES II-A, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-09-23T19:11:31.000Z","date":"2020-09-21","kind":"exercise","acquired":true,"shares":2087130,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On September 21, 2020, the Series B Preferred Stock automatically converted into Common Stock on a 3.3169-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are held directly by Vida Ventures II, LLC (\"Vida II\"). VV Manager II, LLC (\"VV Manager II\") is the manager of Vida II. Arie Belldegrun, Fred Cohen, and Leonard Potter are the members of the management committee of VV Manager II (the \"Management Committee\") and Stefan Vitorovic, Arjun Goyal, Helen Kim, Rajul Jain, and Joshua Kazam are the members of the investment committee of VV Manager II (the \"Investment Committee\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"(Continued from Footnote 2) Each of the Management Committee, the Investment Committee  and the respective members thereof may be deemed to share voting and dispositive power over the shares held by Vida II. VV Manager II, the Management Committee, the Investment Committee and each member of each of the Management Committee and Investment Committee disclaims beneficial ownership over the securities held of record by Vida II and this report shall not be deemed an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interest therein."}],"balance_after":2087130,"source":{"system":"sec-edgar","filing":"0000899243-20-026193","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1824569/000089924320026193/doc4.xml","form_type":"4"}}]}